| 3.15 -0.15 (-4.55%) | 05-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5  |
1-year : | 5.93 |
| Resists | First : | 4.28 |
Second : | 5.07 |
| Pivot price | 3.65 |
|||
| Supports | First : | 3 |
Second : | 2.5 |
| MAs | MA(5) : | 3.47 |
MA(20) : | 3.64 |
| MA(100) : | 6.25 |
MA(250) : | 24.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 21.9 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 96.5 | Low : | 2.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BDRX ] has closed above bottom band by 27.5%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 87 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.24 - 3.27 | 3.27 - 3.28 |
| Low: | 3.04 - 3.07 | 3.07 - 3.1 |
| Close: | 3.11 - 3.15 | 3.15 - 3.18 |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Fri, 15 May 2026
Armistice Capital and Steven Boyd report 9.99% in Biodexa (BDRX) - Stock Titan
Fri, 15 May 2026
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Thu, 14 May 2026
Biodexa Pharmaceuticals Proposes Major Share Capital Reorganization Ahead of June AGM - TipRanks
Thu, 14 May 2026
Biodexa Pharmaceuticals (Nasdaq: BDRX) sets AGM on 10,000:1 reverse split and £25M share authority - Stock Titan
Thu, 14 May 2026
Biodexa proposes share capital reorganization at June meeting - Investing.com
Thu, 14 May 2026
Biodexa plans to shrink 373B shares without cutting ADS stakes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 26,420 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 52.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -26.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -61.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -5.86 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|